You have free access to this content

Alimentary Pharmacology & Therapeutics

Cover image for Alimentary Pharmacology & Therapeutics

April 2013

Volume 37, Issue 7

Pages 659–766

  1. REVIEW ARTICLE

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  2. META-ANALYSIS

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Meta-analysis: oral or enteral nutritional supplementation in cirrhosis (pages 672–679)

      M. Ney, B. Vandermeer, S. J. V. van Zanten, M. M. Ma, L. Gramlich and P. Tandon

      Article first published online: 20 FEB 2013 | DOI: 10.1111/apt.12252

  3. RANDOMISED CLINICAL TRIAL

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo-controlled study (pages 680–690)

      W. Kruis, E. Meier, M. Schumacher, O. Mickisch, R. Greinwald, R. Mueller and the German SAG-20 Study Group

      Article first published online: 17 FEB 2013 | DOI: 10.1111/apt.12248

    2. You have full text access to this OnlineOpen article
  4. ALCOHOL AND HEPATITIS C

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  5. HEPATITIS B

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B (pages 710–719)

      J. L. Hartono, M. O. Aung, Y. Y. Dan, M. Gowans, K. Lim, Y. M. Lee, G. H. Lee, H. C. Low, P. S. Tan, M. A. Thwin, C. Soon, L.-L. Chiu, M. J. Khoo, E. Koay and S. G. Lim

      Article first published online: 21 FEB 2013 | DOI: 10.1111/apt.12251

  6. NAFLD

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
      Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease (pages 720–729)

      M. D. Beaton, S. Chakrabarti, M. Levstik, M. Speechley, P. Marotta and P. Adams

      Article first published online: 26 FEB 2013 | DOI: 10.1111/apt.12255

  7. GASTRO-OESOPHAGEAL REFLUX DISEASE

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  8. RISKS OF ASPIRIN

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
  9. INVITED COMMENTARIES

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  10. LETTERS TO THE EDITORS

    1. Top of page
    2. REVIEW ARTICLE
    3. META-ANALYSIS
    4. RANDOMISED CLINICAL TRIAL
    5. ALCOHOL AND HEPATITIS C
    6. HEPATITIS B
    7. NAFLD
    8. GASTRO-OESOPHAGEAL REFLUX DISEASE
    9. RISKS OF ASPIRIN
    10. INVITED COMMENTARIES
    11. LETTERS TO THE EDITORS
    1. You have free access to this content
    2. You have free access to this content
      Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply (pages 752–753)

      C. Reenaers, E. Louis, J. Belaiche, L. Seidel, S. Keshav and S. Travis

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12245

    3. You have free access to this content
    4. You have free access to this content
    5. You have free access to this content
    6. You have free access to this content
    7. You have free access to this content
      Letter: curing Helicobacter pylori infection in a clinical setting (pages 757–758)

      A. Tursi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12226

      Corrected by:

      Corrigendum: Corrigendum

      Vol. 38, Issue 8, 994, Article first published online: 18 SEP 2013

    8. You have free access to this content
      Letter: curing Helicobacter pylori infection in a clinical setting – authors' reply (pages 758–759)

      F. Thirriot and C. Y. Tay

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12250

      Corrected by:

      Corrigendum: Corrigendum

      Vol. 38, Issue 8, 994, Article first published online: 18 SEP 2013

    9. You have free access to this content
    10. You have free access to this content
      Letter: mucosal healing and mortality in coeliac disease (pages 760–761)

      F. Fernández-Bañares, M. Esteve and J. P. Gisbert

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12229

    11. You have free access to this content
      Letter: Adnab-9 as a potential non-invasive biomarker for prediction of malignancy in coeliac disease (pages 761–762)

      S. Kadauke, A. Picarelli, M. Di Tola, R. K. Parikh, P. Naylor, W.-L. Zhou, J. Bowman, D. Bullock and M. Tobi

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12231

    12. You have free access to this content
      Letter: complications of coeliac disease despite a gluten-free diet – authors' reply (pages 762–763)

      B. Lebwohl, F. Granath, A. Ekbom, S. M. Montgomery, J. A. Murray, A. Rubio-Tapia, P. H. R. Green and J. F. Ludvigsson

      Article first published online: 5 MAR 2013 | DOI: 10.1111/apt.12243

    13. You have free access to this content
    14. You have free access to this content
    15. You have free access to this content

SEARCH

SEARCH BY CITATION